Law360, New York (February 28, 2008, 12:00 AM ET) -- A Dutch court has invalidated a patent for Pfizer Inc.'s Lipitor, but generics drugmaker Ranbaxy Laboratories Inc. is still blocked from launching a generic version of the blockbuster cholesterol drug.
Pfizer announced on Thursday that it would appeal the ruling by the Court of Appeal of The Hague in the Netherlands. The court invalidated Pfizer's patent for atorvastatin enantiomer, an active ingredient of the drug.
Ranbaxy has challenged the validity of Lipitor patents around the world.
But the company is still prevented from launching a generic...
Dutch Court Invalidates Pfizer Lipitor Patent
To view the full article, take a free trial now.
